Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia

Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia

Background Sodium‐glucose cotransporter‐2 inhibitors are cardioprotective independent of glucose control, as demonstrated in animal models of acute myocardial ischemia and clinical trials. The functional and molecular mechanisms of these benefits in the setting of chronic myocardial ischemia are poo...

Full description

Bibliographic Details
Main Authors:	Sharif A. Sabe, Cynthia M. Xu, Mohamed Sabra, Dwight Douglas Harris, Akshay Malhotra, Ahmed Aboulgheit, Madigan Stanley, M. Ruhul Abid, Frank W. Sellke
Format:	Article
Language:	English
Published:	Wiley 2023-01-01
Series:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:	canagliflozin chronic myocardial ischemia coronary disease coronary microcirculation sodium glucose cotransporter 2 inhibitor
Online Access:	https://www.ahajournals.org/doi/10.1161/JAHA.122.028623

Similar Items

Proteomic Profiling of SGLT-2 Inhibitor Canagliflozin in a Swine Model of Chronic Myocardial Ischemia
by: Dwight D. Harris, et al.
Published: (2024-03-01)

Comparative Analysis of Normoxia- and Hypoxia-Modified Extracellular Vesicle Therapy in Function, Perfusion, and Collateralization in Chronically Ischemic Myocardium
by: Sharif A. Sabe, et al.
Published: (2023-01-01)

Effects of canagliflozin on myocardial microvascular density, oxidative stress, and proteomic profile
by: Sharif A. Sabe, et al.
Published: (2023-12-01)

Canagliflozin mitigates ferroptosis and improves myocardial oxidative stress in mice with diabetic cardiomyopathy
by: Shuqin Du, et al.
Published: (2022-10-01)

Sitagliptin therapy improves myocardial perfusion and arteriolar collateralization in chronically ischemic myocardium: A pilot study
by: Sharif A. Sabe, et al.
Published: (2023-06-01)

Acute canagliflozin treatment protects against in vivo myocardial ischemia–reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation
by: Alex Ali Sayour, et al.
Published: (2019-04-01)

EMPA-REG OUTCOME trial and Canagliflozin Cardiovascular Assessment Study: Looking beyond the obvious
by: Rishad Ahmed, et al.
Published: (2017-01-01)

Comparative analysis of instantaneous wave-free ratio and quantitative real-time myocardial contrast echocardiography for the assessment of myocardial perfusion
by: Li Liang, et al.
Published: (2022-10-01)

Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model
by: Ryo Nishinarita, et al.
Published: (2021-01-01)

Findings suggestive of coronary microvascular dysfunction in cats with myocardial ischemia
by: Guillermo Belerenian, et al.
Published: (2021-09-01)

The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following <i>In Vitro</i> Vascular Ischemia/Reperfusion Injury in Rats
by: Sevil Korkmaz-Icöz, et al.
Published: (2021-07-01)

Robustness of Fractional Flow Reserve for Lesion Assessment in Non–Infarct‐Related Arteries of Patients With Myocardial Infarction
by: Jin‐Sin Koh, et al.
Published: (2019-05-01)

Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report
by: Masafumi Fukuda, et al.
Published: (2020-01-01)

Dynamic Changes in Microvascular Flow Conductivity and Perfusion After Myocardial Infarction Shown by Image‐Based Modeling
by: Polyxeni Gkontra, et al.
Published: (2019-04-01)

Remission effect of Canagliflozin in patients with newly diagnosed type 2 diabetes mellitus: a protocol for a multicenter, parallel-group, randomized, controlled, open-label trial
by: Xue Yang, et al.
Published: (2023-10-01)

Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South‐East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial
by: Takashi Wada, et al.
Published: (2022-01-01)

Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy
by: Lakshini Y. Herat, et al.
Published: (2023-04-01)

Synthesis of New Derivatives of Berberine Canagliflozin and Study of Their Antibacterial Activity and Mechanism
by: Jinsheng Li, et al.
Published: (2024-01-01)

Synthesis of Berberine and Canagliflozin Chimera and Investigation into New Antibacterial Activity and Mechanisms
by: Wenhui Hao, et al.
Published: (2022-05-01)

Protective effect of canagliflozin on post-resuscitation myocardial function in a rat model of cardiac arrest
by: Tianfeng Hua, et al.
Published: (2023-11-01)

A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus
by: K M Prasanna Kumar, et al.
Published: (2017-01-01)

Development of canagliflozin nanocrystals sublingual tablets in the presence of sodium caprate permeability enhancer: formulation optimization, characterization, in-vitro, in silico, and in-vivo study
by: Sammar Fathy Elhabal, et al.
Published: (2023-12-01)

Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis
by: Eleanor M. Kellon, et al.
Published: (2022-08-01)

FREQUENCY AND ASSOCIATION OF MYOCARDIAL BRIDGING WITH ATHEROSCLEROTIC CORONARY ARTERY DISEASE IN PATIENTS UNDERGOING CORONARY ANGIOGRAPHY
by: Fahad Shah, et al.
Published: (2019-08-01)

The Use of Canagliflozin in Diabetes Mellitus Type 2 on Renal Outcome: A Systematic Review
by: Vikri Haikal, et al.
Published: (2024-01-01)

DPP‐4 inhibitor sitagliptin treatment results in altered myocardial metabolic proteome and oxidative phosphorylation in a swine model of chronic myocardial ischemia
by: Dwight D. Harris, et al.
Published: (2024-03-01)

Head-to-head comparison of two SGLT-2 inhibitors on AKI outcomes in a rat ischemia-reperfusion model
by: Chang Chu, et al.
Published: (2022-09-01)

Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats
by: Yanjun Cui, et al.
Published: (2022-08-01)

Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin during pregnancy: An ex vivo human placenta perfusion and in vitro study
by: Sabrina Kuoni, et al.
Published: (2024-02-01)

The Efficacy of Canagliflozin on Type 2 Diabetic Nephropathy in Male Rats
by: Manal M.G. Mourad*, et al.
Published: (2023-07-01)

Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
by: Ghazaleh Behnammanesh, et al.
Published: (2019-04-01)

Efficacy of Shexiang Tongxin Dropping Pills in a Swine Model of Coronary Slow Flow
by: Yupeng Bai, et al.
Published: (2022-06-01)

Optimal reperfusion in ST-elevation myocardial infarction – the role of the coronary microcirculation
by: Caterina De, et al.
Published: (2011-12-01)

Investigation of Solubility Behavior of Canagliflozin Hydrate Crystals Combining Crystallographic and Hirshfeld Surface Calculations
by: Yefen Zhu, et al.
Published: (2021-01-01)

Canagliflozin Attenuates Lipotoxicity in Cardiomyocytes by Inhibiting Inflammation and Ferroptosis through Activating AMPK Pathway
by: Wanqiu Zhang, et al.
Published: (2023-01-01)

Study on consequences for interaction of myricetin with canagliflozin: A special attention to pharmacokinetics and pharmacodynamics of drug
by: Naga Raju Kandukoori, et al.
Published: (2023-01-01)

Canagliflozin ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting pulmonary arterial smooth muscle cell proliferation
by: Luxun Tang, et al.
Published: (2023-12-01)

Coronary Microcirculation Downstream Non‐Infarct‐Related Arteries in the Subacute Phase of Myocardial Infarction: Implications for Physiology‐Guided Revascularization
by: Hernán Mejía‐Rentería, et al.
Published: (2019-05-01)

Levosimendan attenuates myocardial injury induced by coronary microembolization in swine by inhibiting myocardial inflammation and apoptosis
by: Han Chen, et al.
Published: (2019-01-01)

Role of Coronary Myogenic Response in Pressure-Flow Autoregulation in Swine: A Meta-Analysis With Coronary Flow Modeling
by: Gregory M. Dick, et al.
Published: (2018-05-01)